ClinicalTrials.Veeva

Menu

Non-specific Effects of FLU-MMR Vaccines in Adults (FLUMMR-BRA)

R

Radboud University Medical Center

Status and phase

Completed
Early Phase 1

Conditions

COVID-19

Treatments

Biological: Influenza
Biological: MMR vaccines
Other: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT05401448
FLUMMR-BRA

Details and patient eligibility

About

Various observational studies have reported an association between influenza vaccination and lower rates of infection with SARS-Cov-2 and less COVID-19 disease severity have been reported in large epidemiological studies in US, Brazil and Italy. Observational studies from the Netherlands showed also strongly reduced COVID-19 infection rates among influenza-vaccinated healthcare workers, with ORs of 0.61 and 0.49 for the first and second wave of COVID-19, respectively. In addition, in-vitro immunological analyses showed that the quadrivalent inactivated influenza vaccine can induce a trained immunity program against SARS-CoV-2 (2). In-vivo vaccination against influenza was also shown to induce improved interferon responses against SARS-CoV-2, with modulation of hyperinflammatory responses. Trained immunity could be the underlying mechanism for the potential protective effect of influenza vaccine, a mechanism that has also been proven for BCG vaccination, and epidemiological evidence suggests similar non-specific effects of MMR and OPV vaccination. Currently, various clinical trials are being conducted to study the impact of BCG, MMR and OPV vaccination on COVID-19, but prospective clinical data on influenza vaccination are lacking. Although specific COVID-19 vaccines have been developed and are proven effective, there are important reasons for assessing in a controlled randomized trial the effect of influenza and MMR vaccine on COVID19:

  • Specific COVID-19 vaccines are still not yet available for all segments of the population, and especially not for the majority of the population in developing countries.
  • The emergence of new SARS-CoV-2 variants, especially the P1 variant from Brazil, may very well be associated with reduced response to vaccines. An immunomodulatory protective vaccine that protects in an antigen-independent manner would be of great importance.
  • It would also be conceptually important to know whether influenza and the MMR vaccine can induce heterologous protection against another viral infection, in the context of future pandemics.

Enrollment

638 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

To be eligible to participate in this study, the participant must meet the following criteria:

• Be older than 18 years old. Observation: the elderly is at risk for severe forms of COVID-19, therefore, the evidence in this age group is very relevant. However, they can also be a first priority population to receive a specific vaccine, limiting the time to follow-up on the study. In addition, influenza and MMR vaccines can lead to a lower immune system in the elderly than in young people. Therefore, it is likely that a more rational choice will be to carry out the study in a young population.

Exclusion criteria

Participants will not be included in the study if they present (reported by the research participants):

  • Known allergy to components of influenza and MMR vaccines or serious adverse events to previous administration.
  • Fever (> 38 degrees Celsius) in the last 24 hours.
  • Pregnancy. Note: pregnancy should be avoided for one month after vaccination.
  • Symptoms of active viral or bacterial infection.
  • Documented diagnosis of COVID-19.
  • Vaccination in the last 4 weeks against SARS-CoV-2.
  • Immunocompromised participants. This exclusion category includes: a) infection with the human immunodeficiency virus (HIV-1); b) neutropenic participant with less than 500 neutrophils/mm3; c) participant with organ transplantation; d) participants with bone marrow transplantation; e) participants in chemotherapy treatment; f) participants with primary immunodeficiency; g) participants with severe lymphopenia with less than 400 lymphocytes/mm3; h) treatment with any anti-cytokine medication; i) treatment with oral or intravenous steroids, for example, daily doses of prednisone or equivalent for more than 3 months, or probable use of oral or intravenous steroids within next four weeks.
  • Some type of lymphoma or malignancy in the previous two years.
  • Direct involvement in the design or execution of the study.
  • Absence from work for more than 4 weeks within the next 12 weeks after study admission (vacation, maternity leave, retirement, planned surgery, etc.)

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

638 participants in 3 patient groups, including a placebo group

Placebo
Placebo Comparator group
Description:
sterile 0.9% NaCl
Treatment:
Other: Placebo
Influenza
Experimental group
Description:
Influenza (tetravalent vaccine)
Treatment:
Biological: Influenza
MMR
Experimental group
Description:
measles, mumps, and rubella vaccine
Treatment:
Biological: MMR vaccines

Trial contacts and locations

1

Loading...

Central trial contact

Jéssica dos Santos, PhD; Clayson Moura Gomes, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems